finder.com

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Lyra Therapeutics stock

Own Lyra Therapeutics stock in just a few minutes.

Buy Lyra Therapeutics (LYRA)
Avatar
Jing Jun Ma
Fact checked

Lyra Therapeutics, Inc is a biotechnology business based in the US. Lyra Therapeutics shares (LYRA) are listed on the NASDAQ and all prices are listed in US Dollars. Lyra Therapeutics employs 38 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Lyra Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – LYRA – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

What's in this guide?

  1. LYRA shares summary
  2. Compare share dealing platforms
  3. Is LYRA stock a buy or sell?
  4. Stock performance over time
  5. Can I short LYRA shares?
  6. Lyra Therapeutics's financials
  7. Does Lyra Therapeutics pay a dividend?
  8. Other common questions

Lyra Therapeutics share price

Use our graph to track the performance of LYRA stocks over time.

Lyra Therapeutics shares at a glance

Information last updated 2021-04-29.
52-week range$8.98 - $20.00
50-day moving average $11.93
200-day moving average $11.79
Wall St. target price$26.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) N/A

Buy Lyra Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Go to site
More Info
Robinhood
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Go to site
More Info
Interactive Brokers
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Go to site
More Info
Webull
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Go to site
More Info
Public
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
Go to site
More Info
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Lyra Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Lyra Therapeutics, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Lyra Therapeutics financials

Gross profit TTM $0
Return on assets TTM -28.98%
Return on equity TTM -54.09%
Profit margin 0%
Book value N/A
Market capitalisation $131.1 million

TTM: trailing 12 months

Shorting Lyra Therapeutics shares

There are currently 327,028 Lyra Therapeutics shares held short by investors – that's known as Lyra Therapeutics's "short interest". This figure is 4.1% up from 314,153 last month.

There are a few different ways that this level of interest in shorting Lyra Therapeutics shares can be evaluated.

Lyra Therapeutics's "short interest ratio" (SIR)

Lyra Therapeutics's "short interest ratio" (SIR) is the quantity of Lyra Therapeutics shares currently shorted divided by the average quantity of Lyra Therapeutics shares traded daily (recently around 78801.927710843). Lyra Therapeutics's SIR currently stands at 4.15. In other words for every 100,000 Lyra Therapeutics shares traded daily on the market, roughly 4150 shares are currently held short.

However Lyra Therapeutics's short interest can also be evaluated against the total number of Lyra Therapeutics shares, or, against the total number of tradable Lyra Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Lyra Therapeutics's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Lyra Therapeutics shares in existence, roughly 30 shares are currently held short) or 0.0669% of the tradable shares (for every 100,000 tradable Lyra Therapeutics shares, roughly 67 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Lyra Therapeutics.

Find out more about how you can short Lyra Therapeutics stock.

Lyra Therapeutics share dividends

We're not expecting Lyra Therapeutics to pay a dividend over the next 12 months.

Lyra Therapeutics overview

Lyra Therapeutics, Inc. , a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The company's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. Its product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase II clinical trial; and LYR-220 for CRS patients with and without nasal polyps. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018.

  1. Technical analysis graphic from TradingView, https://uk.tradingview.com Stock prices and other date from EOD Historical Data

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site